FDA plans to relax testing rules to encourage biosimilar drugs: report
Source: SeekingAlpha
2026-03-09 06:44:09 ET
- The U.S. Food and Drug Administration is reportedly easing some requirements for drugmakers developing copycat versions of costly biologic medications in a bid to bring more competition to the market and lower costs.
- The agency plans to reduce the need for some studies that demonstrate the drugs, called biosimilars, are equivalent to the brand-name medications they’re modeled on, according to an FDA official and a document reviewed by Bloomberg News.
- The agency estimates the change could shave $20 million from the cost of developing a new biosimilar drug. The FDA is expected to issue draft guidance as ?soon as Monday.
Read the full article on Seeking Alpha
For further details see:
FDA plans to relax testing rules to encourage biosimilar drugs: report
Regeneron Pharmaceuticals Inc.
NASDAQ: REGN
REGN Trading
1.21% G/L:
$761.85 Last:
1,000,702 Volume:
$767.04 Open:
REGN Latest News
April 02, 2026 04:30:00 pm
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
April 02, 2026 04:30:00 pm
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
REGN Stock Data
$80,621,924,056
100,116,656
N/A
714
N/A
Biotechnology & Life Sciences
Healthcare
US
Tarrytown
